EurekaMag
+ Most Popular
Cunninghamia lanceolata plantations in China
Mammalian lairs in paleo ecological studies and palynology
Studies on technological possibilities in utilization of anhydrous milk fat for production of recombined butter-like products
Should right-sided fibroelastomas be operated upon?
Large esophageal lipoma
Apoptosis in the mammalian thymus during normal histogenesis and under various in vitro and in vivo experimental conditions
Poissons characoides nouveaux ou non signales de l'Ilha do Bananal, Bresil
Desensitizing efficacy of Colgate Sensitive Maximum Strength and Fresh Mint Sensodyne dentifrices
Administration of fluid by subcutaneous infusion: revival of a forgotten method
Tundra mosquito control - an impossible dream?
Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population
Geochemical pattern analysis; method of describing the Southeastern limestone regional aquifer system
Incidence of low birth weights in a hospital of Mexico City
Tabanidae
Graded management intensity of grassland systems for enhancing floristic diversity
Microbiology and biochemistry of cheese and fermented milk
The ember tetra: a new pygmy characid tetra from the Rio das Mortes, Brazil, Hyphessobrycon amandae sp. n. (Pisces, Characoidei)
Risk factors of contrast-induced nephropathy in patients after coronary artery intervention
Renovation of onsite domestic wastewater in a poorly drained soil
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Systolic blood pressure in a population of infants in the first year of life: the Brompton study
Haematological studies in rats fed with metanil yellow
Studies on pasteurellosis. I. A new species of Pasteurella encountered in chronic fowl cholera
Dormancy breaking and germination of Acacia salicina Lindl. seeds
therapy of lupus nephritis. a two-year prospective study

Treatment of canine non-indolent T cell lymphoma using the VELCAP-TSC protocol: A retrospective evaluation of 70 dogs (2003-2013)


Treatment of canine non-indolent T cell lymphoma using the VELCAP-TSC protocol: A retrospective evaluation of 70 dogs (2003-2013)



Veterinary Journal 211: 39-44



ISSN/ISBN: 1532-2971

PMID: 27017053

DOI: 10.1016/j.tvjl.2016.03.003

The immunophenotype of canine non-indolent lymphoma has prognostic value; dogs with T cell lymphoma have a poorer response rate and shorter survival times than dogs with B cell lymphoma. This study sought to retrospectively evaluate prognostic factors for complete remission (CR), progression free survival (PFS) and overall survival time (OST) in 70 dogs with T cell lymphoma treated with an alkylator-rich, combination protocol. The overall remission was 72.9%; 45 dogs (64.3%) achieved CR and six (8.6%) achieved partial remission. Dogs that were neutropenic at diagnosis were significantly more likely to achieve CR. The median overall PFS was 175 days; 1, 2 and 3 year PFS were 26.8%, 15.8%, and 12.6%, retrospectively, after commencing chemotherapy. Median PFS was significantly longer for dogs that achieved CR. Median OST was 237 days. The 1, 2 and 3 year survival rates were 31%, 20.2% and 11.5%, retrospectively, after commencing chemotherapy. The median OST was significantly longer for dogs that achieved CR and significantly shorter for Boxers and those in substage b at diagnosis. More than 30% of dogs treated with this protocol survived >1 year, suggesting that favourable outcomes and longer survival are possible for a proportion of dogs with T cell lymphoma.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059167719

Download citation: RISBibTeXText

Related references

Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. Journal of Veterinary Internal Medicine 15(4): 348-354, 2001

A combination chemotherapy protocol with MOPP and CCNU consolidation (Tufts VELCAP-SC) for the treatment of canine lymphoma. Veterinary and Comparative Oncology 1(4): 180-190, 2003

A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. Journal of Veterinary Internal Medicine 12(6): 465-470, 1998

A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. Journal of Veterinary Internal Medicine 20(2): 355-364, 2006

Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol. Veterinary and Comparative Oncology 14 Suppl. 1: 147-155, 2016

Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma. Veterinary and Comparative Oncology 11(4): 306-315, 2013

Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance for the treatment of canine lymphoma. Veterinary And Comparative Oncology: 1, 11-22, 2010

Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma. Veterinary and Comparative Oncology 8(1): 11-22, 2010

Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Hematological Oncology 33(4): 136-144, 2015

Risk factors for the development of a second melanoma in patients with cutaneous melanoma. References 34(10): 2295-2302, 2020

Efficacy and toxicosis of VELCAP-C treatment of lymphoma in cats. Journal of Veterinary Internal Medicine 22(1): 153-157, 2008

Biology and treatment of indolent lymphomas: follicular lymphoma and marginal zone B-cell lymphoma. Japanese Journal of Clinical Hematology 50(10): 1332-1341, 2009

Oral cyclophosphamide therapy for patients with residual or relapsed indolent-type lymphoma after initial treatment for aggressive lymphomas. A sub-group of patients with apparent transformed indolent lymphoma. Leukemia and Lymphoma 43(9): 1803-1806, 2002

Promising activity of the proteasome inhibitor bortezomib in the treatment of indolent Non-Hodgkins lymphoma and mantle cell lymphoma. Blood 102(11): 636a, 2003

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 29(9): 1198-1203, 2011